Echocardiography showed that mice that underwent interrupted CIH exposure or received AAV9-PHD3 treatment exhibited higher LVEF and FS than mice in the TAC+CIH group (Figure 6C). The gene discussed is EGLN3; the disease is persistent truncus arteriosus.